Sofosbuvir + Ribavirin in HCV-HIV Coinfection: HCV GT 1,2,3,4

PHOTON-2 Trial

Sofosbuvir plus Ribavirin for HCV-HIV Coinfection
PHOTON-2 Trial: Study Features

PHOTON-2 Trial: Features

- **Design**: Open-label, nonrandomized, uncontrolled, phase 3 trial using sofosbuvir + ribavirin for HCV GT 1, 2, 3, or 4 in persons coinfected with HIV
- **Setting**: 45 clinics in Europe
- **Entry Criteria**
  - HIV coinfection; HCV Genotype 1, 2, 3, or 4
  - Age 18 or older
  - HCV treatment naïve (GT 1-4) or treatment experienced (GT 2 or 3)
  - On HIV ARV Rx with HIV RNA ≤ 50 copies/ml and CD4 >200 cells/mm^3
  - Not on HIV ARV Rx and CD4 > 500 cells/mm^3
  - ARV regimen allowed: tenofovir-emtricitabine plus either ritonavir boosted atazanavir or darunavir, efavirenz, rilpivirine, or raltegravir
  - Compensated cirrhosis permitted (up to 20% of subjects); no platelet cutoff
- **Primary End-Points**
  - Efficacy (SVR12), safety, and impact on HIV

Source: Molina JM, et al. Lancet. 2015;385:1098-106.

Sofosbuvir plus Ribavirin for HCV-HIV Coinfection
PHOTON-2 Trial: Treatment Arms



Drug Dosing

Sofosbuvir: 400 mg once daily

Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg

Source: Molina JM, et al. Lancet. 2015;385:1098-106.

Sofosbuvir plus Ribavirin for HCV-HIV Coinfection
PHOTON-2 Trial: Results

PHOTON-2: SVR12 with Sofosbuvir + RBV x 12-24 weeks



Source: Molina JM, et al. Lancet. 2015;385:1098-106.

Sofosbuvir plus Ribavirin for HCV-HIV Coinfection
PHOTON-2 Trial: Results

PHOTON-2: SVR12 with Sofosbuvir + RBV, by Genotype



Source: Molina JM, et al. Lancet. 2015;385:1098-106.

Sofosbuvir and Ribavirin for HCV-HIV Coinfection
PHOTON-2 Trial: Interpretation

Interpretation: “Sofosbuvir and ribavirin provided high rates of sustained virological response after 12 weeks of treatment in treatment-naive and treatment-experienced patients co-infected with HIV and HCV genotypes 1–4. The characteristics of this interferon-free combination regimen make sofosbuvir plus ribavirin a useful treatment option for this patient population.”

Source: Molina JM, et al. Lancet. 2015;385:1098-106.

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

National HIV Curriculum

AETC AIDS Education & Training Center Program
National Coordinating Resource Center